Recent Analysts’ Ratings Changes for PROCEPT BioRobotics (PRCT)

PROCEPT BioRobotics (NASDAQ: PRCT) has recently received a number of price target changes and ratings updates:

• 10/16/2026 – PROCEPT BioRobotics was upgraded by Piper Sandler to “strong-buy”.
• 10/15/2026 – PROCEPT BioRobotics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 10/6/2026 – PROCEPT BioRobotics is now covered by Barclays. They set an “overweight” rating and a $30.00 price target on the stock.
• 10/6/2026 – PROCEPT BioRobotics was upgraded by Barclays to “strong-buy”.
• 9/9/2026 – PROCEPT BioRobotics had its “market perform” rating reaffirmed by Oppenheimer.

Insider Activity

In other PROCEPT BioRobotics news, CEO Larry Wood acquired 23,900 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares in the company, valued at $498,315. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 1,043 shares of company stock valued at $21,851 in the last 90 days. 4.00% of the stock is owned by company insiders.

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.